|
Clinical trials of bivalirudin
Clinical trials of bivalirudin and meta-analysis are available for the following clinical conditions:
acute coronary syndrome
acute coronary syndrome, antithrombotics, all type of patient
Bivalirudin vs eptifibatide + heparin :
PROTECT-TIMI 30, 2006
-
Bivalirudin vs heparin :
HERO, 1997
-
BAT (Bittl), 1995
-
acute coronary syndrome, antithrombotics, patients managed with an early invasive strategy
bivalirudin vs heparin + GP2b3a inhibitors :
ACUITY (biva alone vs hep+aGP2b3a), 2006
-
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006
-
acute coronary syndrome, antithrombotics, PCI sub group
bivalirudin vs heparin + GP2b3a inhibitors :
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007
-
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007
-
acute myocardial infarction
acute myocardial infarction, antithrombotics, all type of patients
Horizons, 2008
-
Bivalirudin vs heparin :
HERO, 1997
-
acute myocardial infarction, anticoagulant, all type of patients
Horizons, 2008
-
percutaneous coronary intervention
percutaneous coronary intervention, antithrombotics, all type of patients
bivalirudin vs actionated heparin plus tirofiban :
NAPLES (Tavano), 2009
-
Prasugrel and Bivalirudin vs Clopidogrel and Heparin :
BRAVE-4,
-
bivalirudin vs heparin + anti Gp2b3a :
ACUITY (sub groups, bivalirudin alone), 2007
-
ACUITY (Stone) (bivalirudin alone), 2006
-
ACUITY (sub groups, bivalirudin +aGP2b3a), 2007
-
bivalirudin + eptifibatide vs heparin + eptifibatide :
Kleiman, 2002
-
bivalirudin vs Heparin plus GP IIb/IIIa inhibitor :
HORIZONS-AMI (Stone), 2008
-
bivalirudin vs hepatin + anti Gp2b3a :
REPLACE-2, 2003
-
bivalirudin vs LMWH :
CACHET (without abciximab), 2002
-
bivalirudin vs no control :
Topol, 1993
-
bivalirudin vs UFH :
ISAR-REACT 3, 2008
-
REPLACE-1, 2004
-
BAT (Bittl), 1995
-
percutaneous coronary intervention, anticoagulant, all type of patients
bivalirudin vs actionated heparin plus tirofiban :
NAPLES (Tavano), 2009
-
bivalirudin vs heparin + anti Gp2b3a :
ACUITY (sub groups, bivalirudin alone), 2007
-
ACUITY (Stone) (bivalirudin alone), 2006
-
ACUITY (sub groups, bivalirudin +aGP2b3a), 2007
-
bivalirudin + eptifibatide vs heparin + eptifibatide :
Kleiman, 2002
-
bivalirudin vs Heparin plus GP IIb/IIIa inhibitor :
HORIZONS-AMI (Stone), 2008
-
bivalirudin vs hepatin + anti Gp2b3a :
REPLACE-2, 2003
-
bivalirudin vs LMWH :
CACHET (without abciximab), 2002
-
bivalirudin vs no control :
Topol, 1993
-
bivalirudin vs UFH :
ISAR-REACT 3, 2008
-
REPLACE-1, 2004
-
BAT (Bittl), 1995
-
post myocardial infarction
post myocardial infarction, anticoagulant, all type of patients
Horizons, 2008
-
Entry terms: Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, bivalirudin, Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64), Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen, Hirulog-1, Hirulog, Angiomax, The Medicines Company brand of bivalirudin, BG 8967, BG8967, BG-8967
See also relatic topics:
Search bivalirudin clinical trials in
Pubmed
Search bivalirudin clinical trials in
ClinicalTrials.gov
Search bivalirudin clinical trials in
Wikipedia
Search bivalirudin in
drugs.com
browse_trt3
|
|